Skip to main content
main-content

13.07.2016 | Onkologie | Onlineartikel

Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide

The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten